IT
This clinical-stage company develops targeted formulations for the treatment of ocular inflammation, utilizing a platform that integrates immunology and ophthalmology for precise tissue delivery. By addressing inflammation at its source in both the anterior and posterior segments of the eye, the company enhances treatment efficacy and safety for patients with ocular diseases.
Updated 2 months ago
Funding
$30M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- This clinical-stage company develops targeted formulations for the treatment of ocular inflammation, utilizing a platform that integrates immunology and ophthalmology for precise tissue delivery. By addressing inflammation at its source in both the anterior and posterior segments of the eye, the company enhances treatment efficacy and safety for patients with ocular diseases.